| Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection (NCT05413850) | Blue Earth Therapeutics Ltd | 2022-07-20 |
| Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (NCT05340374) | Peter MacCallum Cancer Centre, Australia | 2022-07-14 |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (NCT05113537) | Vadim S Koshkin | 2022-07-08 |
| Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer (NCT05156905) | University of California, San Diego | 2022-06-16 |
| Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04754191) | University of Utah | 2022-06-05 |
| Pamiparib in mCRPC With HRD or BRCA1/2 Mutation (NCT05327621) | Sun Yat-sen University | 2022-05-01 |
| MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer (NCT05127850) | University of California, San Francisco | 2022-03-22 |
| PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer (NCT05245006) | Robert Flavell, MD, PhD | 2022-03-18 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (NCT05241613) | Accutar Biotechnology Inc | 2022-03-16 |
| Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer (NCT05081193) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2022-03-07 |
| FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (NCT05011188) | Rahul Aggarwal | 2022-01-19 |
| Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer (NCT05369000) | Lava Therapeutics | 2022-01-17 |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (NCT05177770) | Coherus Oncology, Inc. | 2022-01-17 |
| Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (NCT05219500) | Fusion Pharmaceuticals Inc. | 2021-12-16 |
| A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT05252364) | Hinova Pharmaceuticals Aus Pty Ltd | 2021-12-14 |
| IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer (NCT05124795) | Immunic AG | 2021-12-09 |
| The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (NCT05262608) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-12-07 |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (NCT05125016) | Regeneron Pharmaceuticals | 2021-11-30 |
| Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) (NCT05116579) | Sun Yat-sen University | 2021-10-31 |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT05005728) | Xencor, Inc. | 2021-10-22 |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer (NCT04986423) | Zenith Epigenetics | 2021-09-08 |
| Abemaciclib With or Without Atezolizumab for mCRPC (NCT04751929) | Dana-Farber Cancer Institute | 2021-08-20 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression (NCT04927663) | Rahul Aggarwal | 2021-08-10 |
| A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer (NCT04869488) | Jiangsu HengRui Medicine Co., Ltd. | 2021-07-19 |
| Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC (NCT04846478) | Dana-Farber Cancer Institute | 2021-06-28 |
| Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (NCT05171816) | AstraZeneca | 2021-06-24 |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer (NCT04729114) | Astellas Pharma Global Development, Inc. | 2021-06-14 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets (NCT04853498) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-09 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (NCT04925284) | Exelixis | 2021-06-07 |
| Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC (NCT04629781) | Swiss Cancer Institute | 2021-05-28 |
| ProsTIC Registry of Men Treated With PSMA Theranostics (NCT04769817) | Peter MacCallum Cancer Centre, Australia | 2021-05-19 |
| Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC (NCT04634344) | Dizal Pharmaceuticals | 2021-04-12 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (NCT04676334) | pharmaand GmbH | 2021-03-22 |
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (NCT04703920) | University of Michigan Rogel Cancer Center | 2021-03-04 |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (NCT04647526) | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 2021-02-25 |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer (NCT04666129) | Sumitomo Pharma America, Inc. | 2021-02-18 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (NCT04726332) | Exelixis | 2021-02-10 |
| Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (NCT04408924) | Eli Lilly and Company | 2021-01-20 |
| Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT04631601) | Amgen | 2021-01-15 |
| A Study of FT-7051 in Men With MCRPC (NCT04575766) | Novo Nordisk A/S | 2020-12-30 |
| SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT04676607) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-12-17 |
| Abiraterone Acetate in Combination With Tildrakizumab (NCT04458311) | Institute of Cancer Research, United Kingdom | 2020-12-01 |
| [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. (NCT04509557) | FutureChem | 2020-10-14 |
| PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT04556617) | Opna Bio LLC | 2020-09-21 |
| Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (NCT04109729) | University of Utah | 2020-09-16 |
| SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (NCT04486937) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-08-30 |
| Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (NCT04419402) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2020-08-17 |
| A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (NCT04237584) | MANA RBM | 2020-06-30 |
| Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma (NCT04586543) | László Mangel | 2020-05-18 |
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer (NCT04253262) | Brown University | 2020-04-03 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (NCT04249947) | Poseida Therapeutics, Inc. | 2020-02-28 |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (NCT04104893) | VA Office of Research and Development | 2020-02-20 |
| PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn (NCT04256993) | Bayer | 2020-02-15 |
| 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies (NCT04158245) | Tulane University | 2020-01-30 |
| Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (NCT04225910) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2020-01-01 |
| 3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer (NCT04000776) | Université de Sherbrooke | 2019-12-16 |
| Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (NCT04179396) | pharmaand GmbH | 2019-12-05 |
| Checkpoint Inhibitors and SBRT for MCRPC (NCT05655715) | Herlev and Gentofte Hospital | 2019-11-25 |
| A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer (NCT04227275) | Tceleron Therapeutics, Inc. | 2019-11-22 |
| A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (NCT04179864) | Epizyme, Inc. | 2019-11-18 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (NCT04068896) | NGM Biopharmaceuticals, Inc | 2019-10-16 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (NCT04104776) | Novartis Pharmaceuticals | 2019-09-18 |
| Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (NCT04060394) | Laekna Limited | 2019-09-13 |
| PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (NCT03658447) | Peter MacCallum Cancer Centre, Australia | 2019-07-12 |
| Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (NCT03835533) | Parker Institute for Cancer Immunotherapy | 2019-06-21 |
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (NCT03531827) | National Cancer Institute (NCI) | 2019-03-26 |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166) | Exelixis | 2019-03-20 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC (NCT03792841) | Amgen | 2019-02-05 |
| Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC (NCT03770455) | Jodi Layton, MD | 2019-01-25 |
| To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer (NCT03752099) | Veru Inc. | 2019-01-18 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer (NCT04188587) | Nanjing First Hospital, Nanjing Medical University | 2019-01-01 |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (NCT03570619) | University of Michigan Rogel Cancer Center | 2018-12-14 |
| Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer (NCT03692663) | Allife Medical Science and Technology Co., Ltd. | 2018-12-01 |
| Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (NCT03732820) | AstraZeneca | 2018-10-31 |
| Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03414034) | Cardiff Oncology | 2018-08-14 |
| Study to Evaluate CCS1477 in Advanced Tumours (NCT03568656) | CellCentric Ltd. | 2018-07-23 |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (NCT03493945) | National Cancer Institute (NCI) | 2018-05-01 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer (NCT03780075) | Peking Union Medical College Hospital | 2018-04-15 |
| Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03437941) | Corcept Therapeutics | 2018-02-20 |
| A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch (NCT03778047) | Hinova Pharmaceuticals Inc. | 2018-02-07 |
| 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT03403595) | Peking Union Medical College Hospital | 2017-12-01 |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden (NCT03328364) | Astellas Pharma a/s | 2017-12-01 |
| Combination Study of AZD5069 and Enzalutamide. (NCT03177187) | Institute of Cancer Research, United Kingdom | 2017-11-13 |
| A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics (NCT03776968) | Hinova Pharmaceuticals Inc. | 2017-10-24 |
| Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (NCT03230734) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2017-09-01 |
| A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03137758) | Pellficure Pharmaceuticals, Inc | 2017-07-24 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (NCT02975934) | pharmaand GmbH | 2017-06-13 |
| Tissue Predictors of Abiraterone Benefit (NCT03176381) | Tianjin Medical University Second Hospital | 2017-05-05 |
| Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC (NCT03085966) | Shanghai AbelZeta Ltd. | 2017-02-27 |
| A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (NCT02952534) | pharmaand GmbH | 2017-02-15 |
| A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. (NCT03774056) | Hinova Pharmaceuticals Inc. | 2017-02-10 |
| Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) (NCT02987543) | AstraZeneca | 2017-02-06 |
| A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (NCT02991911) | MedImmune LLC | 2017-01-06 |
| A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02711956) | Zenith Epigenetics | 2016-12-01 |
| Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors (NCT02744287) | Regeneron Pharmaceuticals | 2016-11-30 |
| Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) (NCT02787005) | Merck Sharp & Dohme LLC | 2016-07-01 |
| A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02705469) | Zenith Epigenetics | 2016-05-01 |